Aim: We aimed to provide a retrospective
evaluation of our kidney transplantation cases.
Material and methods: Demographic characteristics,
cadaver and live donor use numbers, kinship status, hospital stay, postoperative
morbidity, graft loss and mortality rates were determined.
Results: The mean age of the patients was
37.6 ± 16.2 ( 3 - 67) years, 61.7% were male and 38.3% were female. Ninety-seven
percent of our patients underwent living donor kidney transplantation. The
average length of stay in hospital was 11 days. Eight point three percent of
the patients had rejection and the rate of graft loss was 3.3 %. Mortality rate
was 4.2 %.
Conclusion:
The most effective treatment for end-stage renal failure patients is
renal transplantation. The main goal in terms of patient health and comfort
should be to increase the number of kidney transplants.
Amaç: Bu çalışma ile merkezimiz de yapılan böbrek nakli olgularımızı
retrospektif olarak değerlendirmeyi amaçladık.
Gereç ve Yöntem: Hastaların demografik özellikleri, kadavra ve canlı donör kullanım
sayıları, akrabalık durumları, hastanede yatış süreleri, postoperatif morbidite,
greft kaybı ve mortalite oranları belirlendi.
Bulgular: Hastaların yaş ortalaması 37.6 ± 16.2
(3 - 67) idi, % 61.7’ si erkek ve % 38.3’ü
kadındı. Hastalarımızın % 91.7’ sine canlı vericiden böbrek nakli yapıldı. Ortalama
yatıs süresi 11 gündü. Hastaların %
8.3’ünde rejeksiyon görüldü ve greft
kaybı oranı % 3.3 idi. Mortalite oranı % 4.2 idi.
Sonuç: Son dönem böbrek yetmezliği
nedeniyle takip edilen hastalar için en etkin tedavi yöntemi böbrek naklidir.
Hasta sağlığı ve konforu açısından esas amaç böbrek nakli sayılarının arttırılması
olmalıdır.
Primary Language | Turkish |
---|---|
Subjects | Health Care Administration |
Journal Section | Original Article |
Authors | |
Publication Date | July 1, 2019 |
Published in Issue | Year 2019 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.